Zai Lab Limited (ZLAB) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $17.08: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 8.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend.
Zai Lab is a commercial-stage global biopharma with substantial operations in Greater China focused on oncology, immunology, neuroscience, and infectious disease, with 7 commercially launched products including ZEJULA, VYVGART, NUZYRA, and AUGTYRO. Revenue is generated from... Read more
Sell if holding. Engine safety override at $17.08: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 8.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 55d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — Zai Lab Limited
Latest news
- NEWS Reported Earlier, Zai Lab's TIVDAK Receives China NMPA Approval Based On Phase 3 innovaTV 301 Trial Demonstrating Statis — benzinga Jun 9, 2026 positive
- NEWS UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session — benzinga May 18, 2026 neutral
- NEWS The FDA Grants Fast Track Designation To Zai Lab's Zocilurtatug Pelitecan (Zoci, formerly ZL-1310) for Extrapulmonary Ne — benzinga May 11, 2026 positive
- NEWS Citigroup Maintains Buy on Zai Lab, Lowers Price Target to $44 — benzinga May 8, 2026 neutral
- NEWS Zai Lab Q1 EPS $(0.46) Beats $(0.54) Estimate, Sales $99.611M Miss $108.450M Estimate — benzinga May 7, 2026 neutral
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicmainland China (all commercial operations)10-K Item 1A: 'A substantial portion of our operations, and all of our commercial operations, are conducted in mainland China'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Revenue shrinking — -6.5% YoY. Growth thesis broken unless recovery story develops.static
Unprofitable operations — net margin -39.3%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.08: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 8.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $15.88. Score 4.5/10, moderate confidence.
Take-profit target: $28.97 (+69.7% upside). Prior stop was $15.88. Stop-loss: $15.88.
Concentration risk — Geographic: mainland China (all commercial operations); Quality below floor (1.6 < 4.0).
Zai Lab Limited trades at a P/E of N/A (forward -10.1). TrendMatrix value score: 8.3/10. Verdict: Sell.
14 analysts cover ZLAB with a consensus score of 3.9/5. Average price target: $33.
What does Zai Lab Limited do?Zai Lab is a commercial-stage global biopharma with substantial operations in Greater China focused on oncology,...
Zai Lab is a commercial-stage global biopharma with substantial operations in Greater China focused on oncology, immunology, neuroscience, and infectious disease, with 7 commercially launched products including ZEJULA, VYVGART, NUZYRA, and AUGTYRO. Revenue is generated from in-licensed product sales across mainland China, Hong Kong, and Macau via NRDL inclusion and supplemental insurance coverage.